Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34238584
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Harnessing immunotherapy to combat COVID-19: A modern snake oil or silver bullet?
#MMPMID34238584
Gunjegaonkar SM
; Shanmugarajan TS
; Arunsundar M
; Arjun UVNV
; Devi K
; Wankhede SB
; Ravichandiran V
Therapie
2021[Jul]; 76
(4
): 335-345
PMID34238584
show ga
Coronavirus disease 2019 (COVID-19), an infectious disease caused by severe acute
respiratory syndrome coronavirus (SARS-CoV-2), has emerged into a global health
and economic menace. Amidst the COVID-19 turmoil, recent failures/uncertain
outcomes in clinical trials involving the anti-malarial (hydroxychloroquine),
anti-viral (remdesivir) or the combination of anti-malarial/antibiotic
(hydroxychloroquine/azithromycin) regimens have predisposed the physicians to
distrust these "highly-touted" drugs for COVID-19. In this milieu, immunotherapy
might be a credible modality to target or modify specific/non-specific immune
responses that interfere with the survival of intracellular pathogens. This
scientific review throws light on the epidemiology of COVID-19, its pathogenesis
and the current clinical scenario of immunotherapeutics including convalescent
plasma (CP), type-1 interferons (IFN-I) and human monoclonal antibodies (mAbs) to
combat COVID-19. The treatment outcomes underscore that immunotherapy might be a
reliable tool to assuage COVID-19-associated immunopathology. However, specific
patient pool studies are warranted to ascertain the precise (re)purposing of
immunotherapeutics for COVID-19.
free
free
free
